This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sane, D. C. Articles by Stack, R. S. Search for Related Content PubMed PubMed Citation Articles by Sane, D. C. Articles by Stack, R. S.

Circulation, Vol 83, 170-175, Copyright © 1991 by American Heart Association

ARTICLES

Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group

DC Sane, DC Stump, EJ Topol, KN Sigmon, WK Clair, DJ Kereiakes, BS George, MF Stoddard, ER Bates and RS Stack
Department of Medicine, Duke University, Durham, N.C.

To determine whether there are differences in responses to thrombolytic therapy in certain populations, the data for the Thrombolysis and Angioplasty in Myocardial Infarction (phase 1) study were analyzed for black and white patients. Baseline variables including risk factors and extent of coronary artery disease were similar in the 352 white and 24 black patients. The time from onset of chest pain to recombinant tissue- type plasminogen activator (rt-PA) therapy and rt-PA dosing regimens were the same in the two groups. The patency rate of the infarct- related artery at 90 minutes was 91% for blacks and was 72% for whites (p = 0.051). Blacks displayed significantly lower nadir fibrinogen levels (0.57 +/- 0.62 versus 1.3 +/- 0.76 g/l, p less than 0.0001), greater delta fibrinogen (baseline-nadir) (2.7 +/- 1.1 versus 1.7 +/- 1.1 g/l, p less than 0.0001), and increased peak levels of fibrin(ogen) degradation products (837 +/- 865 versus 245 +/- 475 micrograms/ml, p less than 0.0001). rt-PA antigen levels tended to be higher in blacks than in whites (2.8 +/- 2.2 versus 2.2 +/- 3.2 micrograms/ml [p = 0.10] at the peak and 1.6 +/- 1.3 versus 0.99 +/- 1.4 micrograms/ml [p = 0.06] at the end of the maintenance infusion). Major clinical outcomes including survival until time of hospital discharge (92% black versus 93% white, p = 0.68) were not significantly different. However, despite undergoing fewer angioplasty procedures (25% versus 46.3%, p = 0.047), blacks received more transfusions (58.8% versus 19.5% were administered greater than or equal to 2 units packed erythrocytes, p = 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				C. Schindler, A. Mueller, P. Bramlage, W. Boecking, W. Kirch, and J. Schweizer Comparison of Selective AT1-Receptor Blockade Versus ACE Inhibition for Restenosis Prophylaxis in Patients With Peripheral Occlusive Arterial Disease After Stent Angioplasty: A Randomized, Controlled, Proof-of-Concept Study Angiology, January 1, 2008; 58(6): 710 - 716. [Abstract] [PDF]

				E. Hager, R. A. Larson, P. J. DiMuzio, and J. V. Lombardi New Techniques and Developments of Stenting for Infrainguinal Arterial Occlusive Disease: Are the Results Any Better Than Balloon Angioplasty Alone? Perspectives in Vascular Surgery and Endovascular Therapy, September 1, 2007; 19(3): 300 - 306. [Abstract] [PDF]

				T. Zeller Current state of endovascular treatment of femoro-popliteal artery disease Vascular Medicine, August 1, 2007; 12(3): 223 - 234. [Abstract] [PDF]

				T. Yamaguchi, E. Mori, K. Minematsu, J. Nakagawara, K. Hashi, I. Saito, Y. Shinohara, and for the Japan Alteplase Clinical Trial (J-ACT) Gro Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset: Japan Alteplase Clinical Trial (J-ACT) * Supplemental Appendix 2 Stroke, July 1, 2006; 37(7): 1810 - 1815. [Abstract] [Full Text] [PDF]

				K. T. Delis The Case for Intermittent Pneumatic Compression of the Lower Extremity as a Novel Treatment in Arterial Claudication Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2005; 17(1): 29 - 42. [Abstract] [PDF]

				M. A. Albert, J. Torres, R. J. Glynn, and P. M Ridker Perspective on Selected Issues in Cardiovascular Disease Research With a Focus on Black Americans Circulation, July 13, 2004; 110(2): e7 - e12. [Full Text] [PDF]

				C. F. Kugler and G. Rudofsky The challenges of treating peripheral arterial disease Vascular Medicine, May 1, 2003; 8(2): 109 - 114. [Abstract] [PDF]

				P. Faries, N. J. Morrissey, V. Teodorescu, E. C. Gravereaux, J. A. Burks JR, A. Carroccio, K. C. Kent, L. H. Hollier, and M. L. Marin Recent Advances in Peripheral Angioplasty and Stenting Angiology, November 1, 2002; 53(6): 617 - 626. [Abstract] [PDF]

				P. W. Armstrong and D. Collen Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 2 Circulation, June 19, 2001; 103(24): 2987 - 2992. [Full Text] [PDF]

				R. P. Ierardi, M. D. Kerstein, H. Wada, P. Khoury, and T. Matsumoto The Role of Percutaneous Transluminal Angioplasty Following Intraarterial Thrombolytic Therapy for Limb-Threatening Ischemia Vascular and Endovascular Surgery, May 1, 1999; 33(3): 283 - 290. [Abstract] [PDF]

				D. J. Moliterno, E. V. Jokinen, A. R. Miserez, R. A. Lange, J. E. Willard, E. Boerwinkle, L. D. Hillis, and H. H. Hobbs No Association Between Plasma Lipoprotein(a) Concentrations and the Presence or Absence of Coronary Atherosclerosis in African-Americans Arterioscler Thromb Vasc Biol, July 1, 1995; 15(7): 850 - 855. [Abstract] [Full Text]

				E. D. Peterson, S. M. Wright, J. Daley, and G. E. Thibault Racial Variation in Cardiac Procedure Use and Survival Following Acute Myocardial Infarction in the Department of Veterans Affairs JAMA, April 20, 1994; 271(15): 1175 - 1180. [Abstract] [PDF]